UNASSIGNED:特应性皮炎(AD)耀斑的短期/中期空气污染暴露程度尚未得到充分研究。该研究的目的是调查短期/中期暴露于空气污染对接受dupilumab治疗的患者AD耀斑的相关性。
UNASSIGNED:观察性病例交叉研究。包括接受dupilumab治疗的中度至重度AD患者。感兴趣的暴露量是粗颗粒物和细颗粒物(PM10,PM2.5)的平均浓度,二氧化氮,和氧化物(NO2,NOx)。在AD耀斑和对照访视前1至60天考虑不同的间隔,定义为最高湿疹面积和严重程度指数评分分别>8和≤7的访视。采用针对系统处理进行调整的条件逻辑回归分析,以估计每10μg/m3污染物浓度的耀斑增加的几率(%)。
UNASSIGNED:检索了528名AD患者中169名患者的数据,这些患者进行了1130次随访和5840次空气污染物浓度测量。平均年龄为41.4±20.3岁;94名(55%)男性。增量优势曲线表明,在所有时间窗口中,所有污染物的AD耀斑均呈显着的正趋势。在60天,每10μg/m3PM10、PM2.5、NOx、NO2浓度增加与82%相关,67%,28%,113%的可能性,分别。
未经授权:在接受dupilumab治疗的患者中,急性空气污染暴露与AD耀斑风险增加相关,且存在剂量-反应关系.
UNASSIGNED: The magnitude of short/medium-term air pollution exposure on atopic dermatitis (AD) flare has not been fully investigated. The aim of the study was to investigate the association of short/medium-term exposure to airborne pollution on AD flares in patients treated with dupilumab.
UNASSIGNED: Observational case-crossover study. Patients with moderate-to-severe AD under treatment with dupilumab were included. The exposure of interest was the mean concentrations of coarse and fine particulate matter (PM10, PM2.5), nitrogen dioxide, and oxides (NO2, NOx). Different intervals were considered at 1 to 60 days before the AD flare and control visit, defined as the visit with the highest Eczema Area and Severity Index scores >8 and ≤7, respectively. A conditional logistic regression analysis adjusted for systemic treatments was employed to estimate the incremental odds (%) of flare every 10 μg/m3 pollutant concentration.
UNASSIGNED: Data on 169 of 528 patients with AD having 1130 follow-up visits and 5840 air pollutant concentration measurements were retrieved. The mean age was 41.4 ± 20.3 years; 94 (55%) men. The incremental odds curve indicated a significant positive trend of AD flare for all pollutants in all time windows. At 60 days, every 10 μg/m3 PM10, PM2.5, NOx, and NO2 increase concentration was associated with 82%, 67%, 28%, and 113% odds of flare, respectively.
UNASSIGNED: In patients treated with dupilumab, acute air pollution exposure is associated with an increased risk for AD flare with a dose-response relationship.